Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Sees Large Decrease in Short Interest

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 327,700 shares, a decrease of 39.8% from the January 15th total of 544,600 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days.

Hansa Biopharma AB (publ) Stock Performance

Shares of OTCMKTS HNSBF opened at $3.00 on Friday. Hansa Biopharma AB has a 12-month low of $2.83 and a 12-month high of $3.65. The firm’s 50-day simple moving average is $2.95 and its 200 day simple moving average is $3.08.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.